Viewing 0 reply threads
  • Author
    • #19853
      John Connor

      Our news section today reports on a new drug, Arbaclofen ER – an extended release formulation of arbaclofen, the R isomer of baclofen, that leverages our proprietary Osmodex® drug delivery system and is being studied for the treatment of spasticity resulting from multiple sclerosis.
      The company are applying to the US Food and Drug Administration for approval.
      I only recently started using Baclofen and for me it has been brilliant.
      If there’s an even better drug than that, hurrah.
      Of course it needs to be approved and for me in the UK it would then have to be separately approved then get through our rather complex NICE process.

      • This topic was modified 1 year, 11 months ago by John Connor.
Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account